| Project/Area Number |
17K15273
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Food science
|
|---|
| Research Institution | Tokyo University of Agriculture |
|---|
Principal Investigator |
SUZUKI Tsukasa 東京農業大学, 応用生物科学部, 助教 (20714588)
|
|---|
| Project Period (FY) |
2017-04-01 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2019)
|
| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2019: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2018: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | AMPK / SRSF1 / 選択的スプライシング |
|---|
| Outline of Final Research Achievements |
AMPK regulates cellular energy homeostasis by inhibiting anabolic processes and activating catabolic processes. Recent studies have demonstrated that metformin, which is an AMPK activator, modifies alternative pr-mRNA splicing. However, no direct substrate of AMPK for alternative pre-mRNA splicing has been reported. In this study, we identified the splicing factor SRSF1 as a novel AMPK substrate. AMPK directly phosphorylated SRSF1 at Ser133 in an RNA recognition motif. Ser133 phosphorylation suppressed the interaction between SRSF1 and specific RNA sequences without altering the subcellular localization of SRSF1. Moreover, AMPK regulated the SRSF1-mediated alternative pre-mRNA splicing of Ron, which is a macrophage-stimulating protein receptor, by suppressing its interaction with exon 12 of Ron pre-mRNA. The findings of this study revealed that the AMPK-dependent phosphorylation of SRSF1 at Ser133 inhibited the ability of SRSF1 to bind RNA and regulated alternative pre-mRNA splicing.
|
| Academic Significance and Societal Importance of the Research Achievements |
AMPKが関与するSRSF1の新たな翻訳後修飾を明らかにしたことによって、SRSF1依存的な選択的スプライシング制御をより詳細なレベルで理解することができる。これにより選択的スプライシングの破綻による疾病の発症機序の理解、そして遺伝性疾患において、変異したエクソンをスキップさせて正常に近いタンパク質を発現させる、エクソンスキッピングと呼ばれる治療法に対する新しいアプローチにもつながる。また、これらの疾患にAMPK活性化剤や阻害剤、そして栄養状態の管理などの手法を用いる応用研究にもつながる。
|
